M
M. Thirlwell
Researcher at McGill University Health Centre
Publications - 26
Citations - 706
M. Thirlwell is an academic researcher from McGill University Health Centre. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 9, co-authored 22 publications receiving 625 citations.
Papers
More filters
Journal ArticleDOI
Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26
Roy E. Smith,Ann M. Brown,Eleftherios P. Mamounas,Stewart J. Anderson,Barry C. Lembersky,James H. Atkins,Henry R. Shibata,Luis Baez,Patricia DeFusco,Enrique Davila,Stuart J. Tipping,James D. Bearden,M. Thirlwell +12 more
TL;DR: When administered as a continuous 24-hour infusion, high-dose paclitaxel results in a higher tumor response rate than when delivered as a 3-hours infusion but does not significantly improve event-free survival or survival.
Journal ArticleDOI
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.
J. Maroun,Lowell Anthony,Normand Blais,Ronald Burkes,Scot D. Dowden,George Dranitsaris,B. Samson,A Shah,M. Thirlwell,Mark Vincent,R. Wong +10 more
TL;DR: Acute medical management of cid includes loperamide or diphenoxylate as first-line agents and hospitalization is recommended for patients with grades 3 and 4 cid; in-hospital care includes rehydration, antibiotic therapy, and octreotide.
Journal ArticleDOI
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
Stephen R. D. Johnston,Shannon Puhalla,Duncan Wheatley,Alistair Ring,Peter A. Barry,Chris Holcombe,Jean Francois Boileau,Louise Provencher,André Robidoux,Mothaffar F. Rimawi,Stuart McIntosh,Ibrahim A. Shalaby,Robert Stein,Robert Stein,M. Thirlwell,David Dolling,James P Morden,Claire Snowdon,Sophie Perry,Chester Cornman,Leona M. Batten,Lisa K. Jeffs,Andrew Dodson,Andrew Dodson,Vera Martins,Arjun Modi,C. Kent Osborne,Katherine L. Pogue-Geile,Maggie C.U. Cheang,Norman Wolmark,Thomas B. Julian,Kate Fisher,Mairead MacKenzie,Maggie Wilcox,Cynthia Huang Bartlett,Maria Koehler,Mitch Dowsett,Mitch Dowsett,Judith M Bliss,Samuel A. Jacobs +39 more
TL;DR: Adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation (Ki-67) in primary ER-positive BC, but did not increase the clinical response rate over 14 weeks, which was possibly related to a concurrent reduction in apoptosis.
Proceedings ArticleDOI
Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
DJ Slamon,Sandra M. Swain,Marc Buyse,M. Martin,Charles E. Geyer,Y-H Im,Tadeusz Pienkowski,S-B Kim,Nicholas J. Robert,Günther G. Steger,J.P. Crown,S. Verma,Wolfgang Eiermann,Joseph P. Costantino,S-A Im,Eleftherios P. Mamounas,Lee S. Schwartzberg,Ahg Paterson,John R. Mackey,Louise Provencher,Michael F. Press,M. Thirlwell,V. Bee-Munteanu,Volkmar Henschel,A Crepelle-Flechais,Norman Wolmark +25 more
TL;DR: A randomized, phase 3, open-label study evaluating the addition of B to 2 different H-chemo regimens to assess the impact of VEGF-A blockade on residual or micrometastatic disease in the adjuvant setting.
Journal ArticleDOI
Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer
Richard L. Schilsky,Jeremey Levin,William H. West,A. Wong,Bruce Colwell,M. Thirlwell,Rafat Ansari,William N. Bell,Robin L. White,Barbara Yates,Paul V. McGuirt,Richard Pazdur +11 more
TL;DR: Although antitumor activity was observed, EU/5-FU did not meet the protocol-specified statistical criteria for equivalence to 5-FU/LV in terms of OS.